Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hikma PharmaceuticalsHKMPF 87 Debt-to-EBITDA is 1.99 as of Dec. 2025, which is 21% above its 10-year median of 1.64. GuruFocus rates HKMPF with a GF Score™ of 87/100 and a GF Value™ of $28.57 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 692 Drug Manufacturers companies, Hikma Pharmaceuticals ranks worse than 53.9% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Hikma Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
HKMPF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.07 Med: 1.64 Max: 2.65
Current: 1.91
During the past 13 years, the highest Debt-to-EBITDA Ratio of Hikma Pharmaceuticals was 2.65. The lowest was 1.07. And the median was 1.64.
HKMPF's Debt-to-EBITDA is ranked worse than 53.9% of 692
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs HKMPF: 1.91
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Hikma Pharmaceuticals Debt-to-EBITDA Related Terms
Hikma Pharmaceuticals Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKMPF vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Hikma Pharmaceuticals (HKMPF) has a Debt-to-EBITDA of 1.99 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hikma Pharmaceuticals. This is 21% above median its historical median of 1.64. Over the past decade, Hikma Pharmaceuticals' Debt-to-EBITDA has ranged from 1.07 to 2.65. According to the industry distribution chart, Hikma Pharmaceuticals ranks #373 out of 692 companies in the Drug Manufacturers industry, placing it in the top 53.9%.
Is Hikma Pharmaceuticals' Debt-to-EBITDA too high?
Hikma Pharmaceuticals' current Debt-to-EBITDA of 1.99 is 21% above median its 10-year median of 1.64. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 2.65. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Hikma Pharmaceuticals' value of 1.99 is 18.5% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #373 out of 692 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #373 out of 692 companies for Debt-to-EBITDA. This places Hikma Pharmaceuticals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Hikma Pharmaceuticals' value of 1.99 is 18.5% above this benchmark. Historically, Hikma Pharmaceuticals' own Debt-to-EBITDA has ranged from 1.07 to 2.65 over the past decade. While the company's 10-year median is 1.64 vs. the industry median of 1.68, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current Debt-to-EBITDA of 1.99 is 18.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hikma Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current Debt-to-EBITDA is 1.99, which is 21% above median its own 10-year median of 1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.57, compared to a current price of $21.56 — trading 24.5% below its estimated fair value. The current Debt-to-EBITDA is 1.99, which is 21% above median its 10-year median of 1.64 and 18.5% above the Drug Manufacturers industry median of 1.68. Hikma Pharmaceuticals' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Debt-to-EBITDA is 1.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $21.56 is trading 24.5% below its estimated GF Value™ of $28.57.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
Debt-to-EBITDA: 1.99 (21% above median its 10-year median of 1.64)
GF Value™: $28.57 vs. price of $21.56 (24.5% below fair value)
Industry Position: 18.5% above the Drug Manufacturers median (#373 of 692)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
87GF Score
Get the complete analysis for HKMPF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
